Author
@himshouse himshouse
grade Cx.com/himshouse ↗
Obsessive single-name HIMS tracker riding the GLP-1/peptide obesity-drug wave.
Aggregates and synthesizes news, analyst actions, channel/ap
trader score
+1.00
hit rate
55%
mean α
+1.00%
signals 14d
75
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 55% hit rate, +1.00% mean alpha, trader score +1.00. Their last-14d mentions, direction-adjusted, have moved -0.8% since posting (mean over 65 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-08-28 | LLY | @himshouse | -0.10 | Unverified rumor says a large 503B pharmacy restarted GLP-1 production | — | tweet ↗ |
| 2026-08-28 | HIMS | @himshouse | +0.20 | Unverified rumor says a large 503B pharmacy restarted GLP-1 production | — | tweet ↗ |
| 2026-08-28 | NVO | @himshouse | -0.10 | Unverified rumor says a large 503B pharmacy restarted GLP-1 production | — | tweet ↗ |
| 2026-08-28 | LLY | @himshouse | +0.05 | Reports 222,000 units of unapproved retatrutide in a U.S.-bound shipment | — | tweet ↗ |
| 2026-08-28 | HIMS | @himshouse | -0.10 | Reports 222,000 units of unapproved retatrutide in a U.S.-bound shipment | — | tweet ↗ |
| 2026-08-28 | NVO | @himshouse | +0.05 | Reports 222,000 units of unapproved retatrutide in a U.S.-bound shipment | — | tweet ↗ |
| 2026-08-28 | HIMS | @himshouse | -0.40 | Reports HIMS down 8% | — | tweet ↗ |
| 2026-08-27 | HIMS | @himshouse | -0.15 | A potential Ro IPO is framed as a discounted comparable and competitive healthcare-growth catalyst. | -8.9% | tweet ↗ |
| 2026-08-27 | LLY | @himshouse | +0.00 | Discusses uncertainty surrounding the nominated FDA leader and her confirmation prospects. | -0.1% | tweet ↗ |
| 2026-08-27 | HIMS | @himshouse | +0.00 | Discusses uncertainty surrounding the nominated FDA leader and her confirmation prospects. | -8.9% | tweet ↗ |
| 2026-08-27 | NVO | @himshouse | +0.00 | Discusses uncertainty surrounding the nominated FDA leader and her confirmation prospects. | -1.4% | tweet ↗ |
| 2026-08-26 | HIMS | @himshouse | +0.30 | Reports Eucalyptus hiring a Germany expansion-market commercial leader. | -3.3% | tweet ↗ |
| 2026-08-26 | HIMS | @himshouse | -0.20 | Describes peptides as a risky gray market shaped by regulatory restrictions. | -3.3% | tweet ↗ |
| 2026-08-26 | LLY | @himshouse | +0.20 | Reports six Lilly lawsuits against gray-market retatrutide vendors and compounders. | -1.2% | tweet ↗ |
| 2026-08-26 | NVO | @himshouse | +0.00 | Reports six Lilly lawsuits against gray-market retatrutide vendors and compounders. | -3.3% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.